March 3, 2026Practical Laboratory Medicine1 citationsOpen Access

Evaluation of the Truenat® chip-based real-time PCR platform for infectious disease diagnostics

JPJoão Renato Rebello Pinho GCGabriela Rampazzo Cruz POPriscila de Meira Oliveria

Key Points

Truenat assays demonstrate reliable diagnostic performance, particularly for COVID-19, indicating their usefulness in various settings.
MTB detection is more effective with Xpert Ultra in low-burden cases, highlighting specific use cases for each method.
Broader clinical validation for malaria and leptospirosis is necessary before adopting Truenat for routine diagnostics.
Point-of-care diagnostics like Truenat could enhance access to testing in resource-limited locations, supporting timely disease management.

Abstract

Truenat assays showed reliable analytical performance, especially for COVID-19. While MTB detection remains more robust with Xpert Ultra in low-burden cases, Truenat provides a viable point-of-care alternative in resource-limited settings. For malaria and leptospirosis, broader clinical validation is needed before routine implementation in our service.

问 AI

Bookmark

View Full Paper